ConductScience.org, home

Paper2462467

Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation.

Schild H and 2 others. Cancer Immunol Immunother, 1989. Cited by 45 papers, by iCite.

Cite this record

ConductScience Library. Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation. Papers, record 2462467. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2462467

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation.
PubMed
Journal
Cancer Immunol Immunother
PubMed
Year
1989
PubMed
Publication types
Comparative Study, Journal Article
PubMed
Citations, by iCite
45
iCite
Relative citation ratio, by iCite
1.06
iCite
Revised in PubMed
2024-04-26
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schild HH
2von Hoegen PP
3Schirrmacher VV

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cell Transformation, ViralMajor topic
Cytotoxicity, ImmunologicMajor topic
Lymphocyte CooperationMajor topic
LymphomaMajor topic
Newcastle disease virusMajor topic
T-LymphocytesMajor topic
Animals
Antigens, Differentiation, T-Lymphocyte
Epitopes
Interleukin-2
Mice
Mice, Inbred DBA
Mice, Nude
Phenotype
Time Factors
Viral Vaccines

Source PubMed

Download CSV of topics

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
192181Virus augmentation of the antigenicity of tumor cell extracts.Adv Cancer Res1979https://conductscience.org/library/papers/92181PubMed
26172493
Interleukin 2 is not sufficient as helper component for the activation of cytotoxic T lymphocytes but synergizes with a late helper effect that is provided by irradiated I-region-incompatible stimulator cells.
J Immunol1982https://conductscience.org/library/papers/6172493PubMed
33155458
T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
J Immunol1985https://conductscience.org/library/papers/3155458PubMed
492180Viral xenogenization of intact tumor cells.Adv Cancer Res1979https://conductscience.org/library/papers/92180PubMed
56159417IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement.J Immunol1980https://conductscience.org/library/papers/6159417PubMed
63156935A rapid colorimetric assay for the determination of IL-2-producing helper T cell frequencies.J Immunol Methods1985https://conductscience.org/library/papers/3156935PubMed
73919312Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells.Nature1985https://conductscience.org/library/papers/3919312PubMed
86415170Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.J Immunol1983https://conductscience.org/library/papers/6415170PubMed
96333273Resistance of metastatic tumor variants to tumor-specific cytotoxic T-lymphocytes not due to defects in expression of restricting major histocompatibility complex molecules in murine cells.Cancer Res1984https://conductscience.org/library/papers/6333273PubMed
106150440Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo.Nature1984https://conductscience.org/library/papers/6150440PubMed
112785093
Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals.
Invasion Metastasis1989https://conductscience.org/library/papers/2785093PubMed
126546769Newcastle disease virus: the effect of monoclonal antibody in the overlay on virus penetration and the immunoselection of variants.J Gen Virol1984https://conductscience.org/library/papers/6546769PubMed
133005417Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.J Immunol1986https://conductscience.org/library/papers/3005417PubMed
14307029T cell growth factor: parameters of production and a quantitative microassay for activity.J Immunol1978https://conductscience.org/library/papers/307029PubMed
152970967Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response.Eur J Immunol1988https://conductscience.org/library/papers/2970967PubMed
166606682Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.J Immunol Methods1983https://conductscience.org/library/papers/6606682PubMed
173514798The biological modification of tumor cells as a means of inducing their regression: an overview.J Biol Response Mod1986https://conductscience.org/library/papers/3514798PubMed
1825290399Strategies for cell-mediated immunotherapy of cancer: killing or help?Immunol Today1986https://conductscience.org/library/papers/25290399PubMed
193930610Alloantigen-activated lymphocytes from mice bearing a spontaneous "nonimmunogenic" adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity.J Immunol1985https://conductscience.org/library/papers/3930610PubMed
202938736The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.Cancer Immunol Immunother1986https://conductscience.org/library/papers/2938736PubMed

See all 25 referencesDownload CSV of references

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 45 citations.

PMIDTitleJournalYearIn PapersSource
42699700Newcastle Disease Virus - Induced Interferons Regulate PD-L1 and MICA Expression in Human Tumor and Normal Cells.Immunotargets Ther2026https://conductscience.org/library/papers/42699700PubMed
39062070Newcastle Disease Virus Virotherapy: Unveiling Oncolytic Efficacy and Immunomodulation.Biomedicines2024https://conductscience.org/library/papers/39062070PubMed
37720338Papaverine Enhances the Oncolytic Effects of Newcastle Disease Virus on Breast Cancer In Vitro and In Vivo.Int J Microbiol2023https://conductscience.org/library/papers/37720338PubMed
36361831Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy.Int J Mol Sci2022https://conductscience.org/library/papers/36361831PubMed
35860357Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy.Front Mol Biosci2022https://conductscience.org/library/papers/35860357PubMed
35327364Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus.Biomedicines2022https://conductscience.org/library/papers/35327364PubMed
34209981Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.Viruses2021https://conductscience.org/library/papers/34209981PubMed
33967605Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.Int J Med Sci2021https://conductscience.org/library/papers/33967605PubMed
33805626Less Can Be More: The Hormesis Theory of Stress Adaptation in the Global Biosphere and Its Implications.Biomedicines2021https://conductscience.org/library/papers/33805626PubMed
32188078Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis.Biomedicines2020https://conductscience.org/library/papers/32188078PubMed
32155856New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection.Biomedicines2020https://conductscience.org/library/papers/32155856PubMed
31480379Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.Biomedicines2019https://conductscience.org/library/papers/31480379PubMed
31338417Tumor Cells Modified with Newcastle Disease Virus Expressing IL-24 as a Cancer Vaccine.Mol Ther Oncolytics2019https://conductscience.org/library/papers/31338417PubMed
28536382Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!Biomedicines2016https://conductscience.org/library/papers/28536382PubMed
28531117Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients.Int J Mol Sci2017https://conductscience.org/library/papers/28531117PubMed
23365495An overview on the development of newcastle disease virus as an anti-cancer therapy.Malays J Med Sci2003https://conductscience.org/library/papers/23365495PubMed
22131816Safety and clinical usage of newcastle disease virus in cancer therapy.J Biomed Biotechnol2011https://conductscience.org/library/papers/22131816PubMed
19565923Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer.Methods Mol Biol2009https://conductscience.org/library/papers/19565923PubMed
8690751Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells.J Cancer Res Clin Oncol1996https://conductscience.org/library/papers/8690751PubMed
7642685Biotherapy of cancer. Perspectives of immunotherapy and gene therapy.J Cancer Res Clin Oncol1995https://conductscience.org/library/papers/7642685PubMed

See all 25 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2462467

GET https://conductscience.org/api/papers/v1/2462467/references?page=2